Dosing & Uses
Dosage Forms & Strengths
topical cream
- 1%
Tinea Corporis
Indicated for the treatment of tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
Apply cream to affected area and ~1-inch surrounding area(s) qDay for 1 week
Tinea Cruris
Indicated for the treatment of tinea cruris caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
Apply cream to affected area and ~1-inch surrounding area(s) qDay for 1 week
Tinea Pedis
Indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
Apply cream to affected area and ~1-inch surrounding area(s) qDay for 2 weeks
Dosage Forms & Strengths
topical cream
- 1%
Tinea Corporis
Indicated for the treatment of tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
<12 years: Safety and efficacy not established
12-18 years: Apply cream to affected area and ~1-inch surrounding area(s) qDay for 1 week
Tinea Cruris
Indicated for the treatment of tinea cruris caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
<12 years: Safety and efficacy not established
12-18 years: Apply cream to affected area and ~1-inch surrounding area(s) qDay for 1 week
Tinea Pedis
Indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum
<2 years: Safety and efficacy not established
2-18 years: Apply cream to affected area and ~1-inch surrounding area(s) qDay for 2 weeks
Adverse Effects
<1%
Application site reactions
Postmarketing Reports
Contact dermatitis
Cellulitis
Warnings
Contraindications
None
Cautions
For topical use only; not for ophthalmic or intravaginal administration
May inhibit CYP2C19 and CYP3A4 isoenzymes; particularly when treating large surface areas (ie, moderate-to-severe tinea cruris) that result in increased luliconazole systemic exposure
Pregnancy & Lactation
Pregnancy
There are no available data with use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage; in animal reproduction studies with pregnant rats and rabbits, there were no adverse developmental effects observed with subcutaneous administration of luliconazole during organogenesis at doses up to 3 and 24 times, respectively, the maximum recommended human dose (MRHD)
Lactation
There is no information available on presence in human milk, effects of drug on breastfed infant, or effects of drug on milk production after topical application to women who are breastfeeding; lack of clinical data during lactation precludes a clear determination of risk to an infant during lactation; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Imidazole antifungal that alters the fungal cell membrane; interacts with 14-alpha demethylase (an enzyme necessary for conversion of lanosterol to ergosterol), inhibiting the synthesis of ergosterol which is an essential component of the membrane; increases cell permeability causing leakage of cellular contents
Absorption
Tinea pedis
- Peak plasma concentration: 0.4 ng/mL (first dose); 0.93 ng/mL (final dose)
- Peak plasma time: 16.9 hr (first dose); 5.8 hr (final dose)
- AUC: 6.88 ng•hr/mL (first dose); 18.74 ng•hr/mL (final dose)
Tinea cruris
- Peak plasma time: 21 hr (first dose); 6.5 hr (final dose)
- Peak plasma concentration: 4.91 ng/mL (first dose); 7.36 ng/mL (final dose)
- AUC: 85.1 ng•hr/mL (first dose); 121.74 ng•hr/mL (final dose)
Distribution
Protein bound: >99%
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Luzu topical - | 1 % cream | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.